Dear all, I've recently performed my first few ELISPOTs.
I'm checking for reactivity towards both CD4 & CD8 tumor neoantigens. I have been using synthetic 29-mers representing the mutant amino acid and 14 flanking residues on each side. I use either tumor-infiltrating lymphocytes (20,000/well) or lymphocytes from the tumor-draining lymph node (50,000/well) as effectors, and naive splenocytes as APCs (500,000/well).
I noticed that the number of spots above background (medium only; just T cells + splenocytes) I get is variable and often times quite low; generally between 5-50 spots above background per antigen. For Concanavalin A stimulation I get about 500-1000 spots per well, and for the positive control antigen I get 10-50 spots above background. I notice that often papers report spot counts in the 100s for antigens. I also notice that almost every other paper I've encountered utilizes 8 to 10-mer peptides for CD8 stimulation, and 15-mer peptides for CD4.
I was wondering if I could also expect a significant increase in spot counts from switching from 29-mer peptides for both CD8 and CD4 stim to using the minimal MHC-I epitope (8 to 10-mer) for CD8 stim and the shorter 15-mer peptides for CD4 stim?